CHRISTINA HULSEY: Open Payments
NPI 1457625766 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,094 in 157 payments from 20 companies in 2025. Trend: 2023 $1,142 · 2024 $3,682 · 2025 $3,094
Food & beverage: $3,094
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 33 | $882 |
| GlaxoSmithKline, LLC. | 24 | $364 |
| Verona Pharma, Inc. | 23 | $332 |
| Regeneron Healthcare Solutions, Inc. | 9 | $247 |
| GENZYME CORPORATION | 14 | $211 |
| United Therapeutics Corporation | 9 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $159 |
| Viatris Specialty LLC | 7 | $146 |
| Baxter Healthcare | 5 | $110 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $76 |
Products named: DUPIXENT, FASENRA, Ohtuvayre, BEVESPI AEROSPHERE, Tyvaso, NUCALA, TRELEGY ELLIPTA, GLASSIA.
Industry payments across OK — which companies pay providers there.
